204 results on '"Farag, Sherif S."'
Search Results
2. Low CD34+ Cell Doses Are Associated with Increased Cost and Worse Outcome after Tandem Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Germ Cell Tumors
3. Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics, and Pharmacodynamics Initial Findings from a Phase 1/2 Study
4. Toxicity and Outcomes of Thiotepa-Based Myeloablative Conditioning in Severely Obese Recipients of Allogeneic Stem Cell Transplant
5. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study
6. The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation
7. sj-docx-1-tah-10.1177_20406207231170708 – Supplemental material for The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation
8. The in Vitro and In Vivo Effects of DPP-4 Inhibition with Sitagliptin, Alone and in Combination with Bortezomib, on T Cell Activation: Rationale for GvHD Prevention
9. The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
10. Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
11. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
12. Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission
13. A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Primary Refractory and Relapsed and Refractory Non-Hodgkin Lymphoma
14. Prophylaxis with Sirolimus and Tacrolimus ± Antithymocyte Globulin Reduces the Risk of Acute Graft-versus-Host Disease without an Overall Survival Benefit Following Allogeneic Stem Cell Transplantation
15. Pre-Transplant M Protein Level Predicts Minimal Residual Disease Status after Autologous Stem Cell Transplantation in Multiple Myeloma
16. Impacts of Total Body Irradiation in Allogeneic Umbilical Cord Blood Hematopoietic Stem Cell Transplantation
17. Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia
18. Differential stem- and progenitor-cell trafficking by prostaglandin [E.sub.2]
19. Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation
20. Histoplasma capsulatum Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient Receiving Voriconazole Prophylaxis
21. 221 - Toxicity and Outcomes of Thiotepa-Based Myeloablative Conditioning in Severely Obese Recipients of Allogeneic Stem Cell Transplant
22. 136 - Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics, and Pharmacodynamics Initial Findings from a Phase 1/2 Study
23. The Effect of KIR Ligand Incompatibility on the Outcome of Unrelated Donor Transplantation: A Report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry
24. High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation
25. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups
26. Mitigating Damage Response with CD24 Fusion Protein for Prevention of Acute Graft-Versus-Host Disease
27. A Prospective Phase II Clinical Trial of CD26/Dipeptidyl Peptidase (DPP)-IV Inhibition for Prevention of Acute Graft Versus Host Disease (aGVHD) Following Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation.
28. Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to Reduce Acute Gvhd: Study Design on a Randomized Double Blind Placebo Controlled Phase III Clinical Trial (CATHY Study)
29. STEPS to Enhance Physical Activity after Hematopoietic Cell Transplantation for Multiple Myeloma
30. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation
31. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
32. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
33. 312 - Impacts of Total Body Irradiation in Allogeneic Umbilical Cord Blood Hematopoietic Stem Cell Transplant with Reduced Intensity Conditioning
34. Higher Sirolimus Levels between Days 11-20 after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Increase the Risk of Hepatic Sinusuoidal Obstruction Syndrome (SOS) after Non-Busulfan Myeloablative Conditioning
35. High-Dose Thiotepa-Cyclophosphamide (TT/Cy) Results in Superior Outcomes Compared with Total Body Irradiation-Cyclophosphamide (TBI/Cy) in Patients with Acute Myeloid Leukemia (AML), Advanced Chronic Myeloid Leukemia (CML) and High-Grade Myelodysplasia (MDS) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
36. Outcomes of Infliximab in Management of Steroid-Refractory Acute Graft Versus Host Disease
37. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
38. Killer Cell Immunoglobulin-Like Receptor Ligand Mismatching: To Match or Mismatch?
39. High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation
40. KIR Bdonors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation
41. Modeling Sitagliptin Effect on Dipeptidyl Peptidase 4 (DPP4) Activity in Adults with Hematological Malignancies After Umbilical Cord Blood (UCB) Hematopoietic Cell Transplant (HCT)
42. Higher CD34+ Cell Doses Reduce the Cost of Tandem Autologous Stem Cell Transplants for Relapsed or Refractory Germ Cell Tumors
43. Inhibition of PIM Kinases Mitigates DNA Repair Responses Following Anthracycline-Induced DNA Damage and Enhances the Anti-Tumor Activity of Doxorubicin Against Lymphoma Cells
44. The in Vitroand In VivoEffects of DPP-4 Inhibition with Sitagliptin, Alone and in Combination with Bortezomib, on T Cell Activation: Rationale for GvHD Prevention
45. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
46. Abstract 5473: The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus
47. Synergistic Activity of Bendamustine in Combination with Doxorubicin and Bortezomib in Multiple Myeloma Cells
48. The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo, and Shows Synergistic Activity in Combination with Lenalidomide
49. Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide
50. A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.